{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Amanam I"],"funding":["NCI NIH HHS"],"pagination":["5086-5095"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7578487"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(9)"],"pubmed_abstract":["<h4>Background</h4><i>KRAS</i> mutations reported in non-small cell lung cancer (NSCLC) represent a significant percentage of patients diagnosed with NSCLC. However, there still remains no therapeutic option designed to target KRAS. In an era with immunotherapy as a dominant treatment option in metastatic NSCLC, the role of immunotherapy in.<h4>Kras</h4>mutated patients is not clear.<h4>Methods</h4>Eligible patients diagnosed with NSCLC and found to have a <i>KRAS</i> mutation were identified in an institutional lung cancer database. Demographic, clinical, and molecular data was collected and analyzed.<h4>Results</h4>A total of 60 patients were identified for this retrospective analysis. Majority of patients were Caucasian (73%), diagnosed with stage IV (70%) adenocarcinoma (87%), and had "],"journal":["Journal of thoracic disease"],"pubmed_title":["Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival."],"pmcid":["PMC7578487"],"funding_grant_id":["P30 CA033572","U54 CA209978","R01 CA218545"],"pubmed_authors":["Gupta R","Pharaon R","Salgia R","Massarelli E","Koczywas M","Achuthan S","Amanam I","Wang Y","Mambetsariev I","Reckamp K"],"additional_accession":[]},"is_claimable":false,"name":"Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival.","description":"<h4>Background</h4><i>KRAS</i> mutations reported in non-small cell lung cancer (NSCLC) represent a significant percentage of patients diagnosed with NSCLC. However, there still remains no therapeutic option designed to target KRAS. In an era with immunotherapy as a dominant treatment option in metastatic NSCLC, the role of immunotherapy in.<h4>Kras</h4>mutated patients is not clear.<h4>Methods</h4>Eligible patients diagnosed with NSCLC and found to have a <i>KRAS</i> mutation were identified in an institutional lung cancer database. Demographic, clinical, and molecular data was collected and analyzed.<h4>Results</h4>A total of 60 patients were identified for this retrospective analysis. Majority of patients were Caucasian (73%), diagnosed with stage IV (70%) adenocarcinoma (87%), and had ","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Sep","modification":"2025-04-25T17:39:00.2Z","creation":"2025-04-06T06:09:20.506Z"},"accession":"S-EPMC7578487","cross_references":{"pubmed":["33145085"],"doi":["10.21037/jtd.2020.04.18"]}}